Kryger Capital’s Drugs Made In America Acquisition Corp Units DMAAU Stock Holding History

Kryger Capital’s Portfolio DMAAU Stock Details DMAAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-303,810	Closed	-$3.04M	–	87
2025 Q4	$3.04M	Buy	303,810 +3,810	+1%	+$40K	0.24%	28
2025 Q3	$2.98M	Buy	+300,000	New	+$3.14M	0.34%	21

Other funds holding DMAAU

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Kryger Capital's DMAAU Position: Q1 2026 in Review

Kryger Capital sold out of Drugs Made In America Acquisition Corp Units (DMAAU) in Q1 2026, closing a stake of 303,810 shares — an estimated $3.04M sold.

Kryger Capital first reported a position in DMAAU in Q3 2025 and held it in 2 quarters. The position peaked at $3.04M in Q4 2025. 2 funds tracked by Wall St. Rank hold DMAAU as of Q1 2026.

Kryger Capital reported no remaining Drugs Made In America Acquisition Corp Units position as of Q1 2026 after selling out during the quarter.
Kryger Capital sold 303,810 Drugs Made In America Acquisition Corp Units shares in Q1 2026, an estimated $3.04M.
Kryger Capital first reported a position in Drugs Made In America Acquisition Corp Units in Q3 2025 and held it in 2 quarters.
Kryger Capital's Drugs Made In America Acquisition Corp Units position peaked at $3.04M in Q4 2025.
2 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Units as of Q1 2026.

Based on Kryger Capital's 13F filing for Q1 2026, filed 14 May 2026.